An Introduction to Stroke
Most strokes (85%) are caused by acute ischaemia due to blockage of a cerebral artery, leading to loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral or subarachnoid haemorrhage. Treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytics and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. Increasingly, oral anticoagulants are preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia (e.g. transplantation of mesenchymal stem cells) are also emerging as potentially useful.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Johanna Ospel, ESOC 2021: Predictors and Clinical Impact of Infarct Progression Rate in the ESCAPE-NA1 Trial
We had the pleasure of meeting up with Dr Johanna Ospel (University Hospital, Basel, Switzerland) to discuss the findings from the ESCAPE-NA1 Trial. The abstract entitled “Predictors and Clinical Impact of Infarct Progression Rate in the ESCAPE-NA1 Trial” was presented at the 7th European Stroke Conference, 1-3 September 2021. Questions: Why is it so important […]
Michael Hill, ESOC 2021: Nerinetide for the treatment of Acute Ischaemic Stroke – ESCAPE-NA1 Trial Results
We had the pleasure of meeting up with Prof. Michael Hill (University of Calgary, Calgary, Canada) to discuss the use of nerinetide in the treatment of patients who had an acute ischaemic stroke, and the findings from the ESCAPE-NA1 trial. The session entitled “Nerinetide for LVO Neuroprotection: Fact or Fiction?” was presented at the 7th […]
Cerebral Amyloid Angiopathy: A Presentation of Non-haemorrhagic Diffuse Encephalopathy Case Report
touchREVIEWS in Neurology. 2021;17(1):64-6 DOI: https://doi.org/10.17925/USN.2021.17.1.64
Cerebral amyloid angiopathy (CAA), also known as congophilic angiopathy, is a recognized cause of lobar intracerebral haemorrhage in patients above the age of 50 years.1 It is known to be due to deposition of a variant of amyloid (beta-amyloid plaque) in cerebral blood vessels. Beta-amyloid plaque is formed by the degradation of amyloid precursor protein via […]
Hanne Christensen, Arlene Wilkie & Francesca Romana Pezzella: Stroke Action Plan for Europe (Part 1)
In conjunction with the European Stroke Organisation (ESO), we had the pleasure of meeting with Prof. Hanne Christensen (Chair, Stroke Action Plan for Europe), Arlene Wilkie (Co-Chair, Stroke Action Plan for Europe), and Dr Francesca Romana Pezzella (Co-Chair, Stroke Action Plan for Europe) to discuss the Stroke Action Plan for Europe (SAP-E), a pan-European project, setting […]
Hanne Christensen, Arlene Wilkie & Francesca Romana Pezzella: Stroke Action Plan for Europe (Part 2)
In conjunction with the European Stroke Organisation (ESO), we had the pleasure of meeting with Prof. Hanne Christensen (Chair, Stroke Action Plan for Europe), Arlene Wilkie (Co-Chair, Stroke Action Plan for Europe), and Dr Francesca Romana Pezzella (Co-Chair, Stroke Action Plan for Europe) to discuss the Stroke Action Plan for Europe (SAP-E), a pan-European project, […]
Anabolic Androgenic Steroid Abuse and Cerebral Venous Thrombosis—A Case Report
US Neurology. 2020;16(2):120–2 DOI: https://doi.org/10.17925/USN.2020.16.2.120
Cerebral venous thrombosis (CVT) is a rare condition.1–3 While thrombophilias, contraceptive pill, hormonal replacement therapy, and neoplasms are well-established predisposing factors, steroid use is a less-common possible risk factor, particularly with regard to anabolic androgenic steroids (AAS).1–4 We intend to describe what is known about AAS and present a case of CVT associated with AAS use […]
Vida Demarin, CONy 2020 – Statins for Stroke Prevention in Older Generations
Vida Demarin (International Institute for Brain Health, Zagreb, Croatia) kindly took the time to speak with us on the topic of the debate session she participated in: Should statins be given to people over age 80 for stroke prevention? As co-Chair of CONy 2021, she also shared her excitement for the next congress, which will be […]
Arlene Wilkie, ESO-WSO 2020 – Stroke Action Plan for Europe
We were delighted to have an opportunity to hear all about the Stroke Action Plan for Europe from Arlene Wilkie, Director General of the Stroke Alliance for Europe (SAFE). Related useful resources: Stroke Alliance for Europe (SAFE) Economic Impact of Stroke in Europe Questions What are the major challenges in stroke care across Europe and […]
Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke
US Neurology. 2020;16(1):54–60 DOI: https://doi.org/10.17925/USN.2020.16.1.54
Globally, a high proportion (around 25%) of transient ischemic attacks (TIAs) and ischemic strokes are cryptogenic.1,2 The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification defines a cryptogenic stroke as a brain infarction that is not caused by definite cardioembolism, large artery atherosclerosis, or small artery disease, despite extensive investigations.3 The “ASCOD” classification defines strokes […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!